Shenzhen Neptunus Interlong Bio-technique Company Limited (HKG:8329)
Hong Kong · Delayed Price · Currency is HKD 0.1230
-0.0070 (-5.38%)
Apr 2, 2026, 3:59 PM HKT
HKG:8329 Revenue
In the year 2025, Shenzhen Neptunus Interlong Bio-technique Company had annual revenue of 972.01M CNY, down -6.69%. Shenzhen Neptunus Interlong Bio-technique Company had revenue of 238.04M in the half year ending December 31, 2025, a decrease of -4.24%.
Revenue
972.01M CNY
Revenue Growth
-6.69%
P/S Ratio
0.19
Revenue / Employee
659.44K CNY
Employees
1,474
Market Cap
206.39M HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 972.01M | -69.69M | -6.69% |
| Dec 31, 2024 | 1.04B | -23.16M | -2.18% |
| Dec 31, 2023 | 1.06B | 78.17M | 7.92% |
| Dec 31, 2022 | 986.69M | 147.89M | 17.63% |
| Dec 31, 2021 | 838.81M | -192.56M | -18.67% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Zhongzhi Pharmaceutical Holdings | 1.93B |
| Lee's Pharmaceutical Holdings | 1.44B |
| Kontafarma China Holdings | 914.71M |
| Wai Yuen Tong Medicine Holdings | 721.27M |
| PuraPharm Corporation | 336.11M |
| Tianda Pharmaceuticals | 322.95M |
| Pak Fah Yeow International | 214.31M |
| Extrawell Pharmaceutical Holdings | 52.65M |